Document is current
Any future updates will be listed below
-
Authors
O’Reilly, Seamus https://orcid.org/0000-0002-2887-7336
Luis, Ines Vaz https://orcid.org/0000-0002-7194-2260
Adam, Virginie https://orcid.org/0000-0002-5271-7287
Razis, Evangelia D. https://orcid.org/0000-0003-3873-2947
Urruticoechea, Ander https://orcid.org/0000-0003-0359-3641
Arahmani, Amal
Carrasco, Eva https://orcid.org/0000-0002-2771-7197
Chua, Boon H. https://orcid.org/0000-0002-7561-7174
Bliss, Judith https://orcid.org/0000-0001-7957-7424
Straehle, Carolyn
Goulioti, Theodora https://orcid.org/0009-0006-0178-5120
Lindholm, Barbro https://orcid.org/0000-0003-1531-630X
Werustsky, Gustavo https://orcid.org/0000-0001-6271-105X
Brain, Etienne https://orcid.org/0000-0003-0881-9371
Bedard, Philippe L. https://orcid.org/0000-0002-6771-2999
Curigliano, Giuseppe https://orcid.org/0000-0003-1781-2518
Loi, Sherene https://orcid.org/0000-0001-6137-9171
Saji, Shigehira https://orcid.org/0000-0002-6732-8030
Cameron, David https://orcid.org/0000-0001-6097-2256
-
Funding
Funding for this research was provided by:
Health Research Board (cancertrials)
European Union (101156800, Horizon, Horizon, Horizon, Horizon)
- License Information
-
More Information
Article History
Received: 3 April 2025
Accepted: 23 May 2025
First Online: 10 July 2025
Competing interests
: Conflict of Interest Travel: Servier (ER), Gilead (ER, EB) Astra Zeneca (ER, EB, GC) Integris (ER), Pfizer (ER, EB), Genesis Pharma (ER), Bristol Myers Squibb (ER), Roche (ER, GC), Daichi Sankyo (EB, GC, SOR), Exact Sciences (EB), Novartis (EB,IVL, SOR), Merck (SOR), Nordic Pharma (SOR)Stocks: Eli Lilly (EC)Honoraria/Lecture Fees: Chugai (SS), Kyowa Kirin (SS), Merck Sharp Dohme (SS, GW), Takeda (SS, EB), Novartis (SS, GW, ER, EB, GC), Daichi Sankyo (SS, GW, EB,GC,BL), Eisai (SS), Eli Lilly (SS, EB, GC), Astra Zeneca (SS, GW, ER, EB, GC), Pfizer (EB, GC, GW,SS), Taiho (SS), Oho (SS), Nippon Kayaku (SS), Gilead (SS, ER), Exact Sciences (SS, GC,EB), Myriad Genetics (SS), Roche (GW,GC), Ser-vier (ER), Foundation Medicine (GC), Samsung (GC), Incyte (EB), Seagen (GC), Menarini (GC), Gilead Sciences (GC), Ellipses Pharma (GC).Consultancy/Advisory RolesGlaxo Smith Kline (GC), Zymeworks (PB), Astra Zeneca (GW,GC, BL, SL), Roche (SL, GC), Janssen (PB), Repare (PB), Eli Lilly (GC, SL, BL,PB), Exact Sciences (SL,EB), Gilead Sciences (GC, SL, BL), Amgen (PB), Foundation Medicine (GC), Bristol Myers Squibb (GC,SL), Samsung (GC), Boehringer Ingelheim (GC), Merck (GC, PB), Blueprint Medicines (GC), Sandoz (EB), Pfizer (EB, GC, BL), Menarini (EB, GC, BL), Exnet Science (GC), Daichi Sankyo (GW, EB, BL), Novartis (GW, GC,SL), Merck Sharp Dohme (GW), Seagen (GC,PB), Guardant Health (GC), Celulicity (GC), Hengrini Therapeutics (GC), Amaroq Therpeutics (SL), Mersana Therpeutics (SL), Domain Therpeutics (SL), BioNTech (SL), Menarini Asia Pacific (SL), Bicycle Therpeutics (SL), Saga Diagnostics (SL), Adanate (SL), Research Funding to InstitutionAmgen (PB, IVL), Signal Chem (PB) Seagen (PB), Servier (PB), Sanofi Aventis (SS, PB, AA, VA, TG, CS), Janssen (JB, GW), Clovis (JB), Bristol Myers Squibb (SL, PB), Lilly Loxo (PB), Medice-na (PB), PTC Thereputics (PB), Life Sciences (PB), Zymeworks (PB), Veracyte (BC, PB), Taiho (SS), Eisai (SS), Chugai (SS), Medimmune (GW), Novartis (IVL, SL, DC, GW, EC, AA, VA, TG, CS, JB, PB), Pfizer (DC, SL, GW, EC, AA, VA, CS, TG, JB), Merck Sharp Doehm (SL,JB,SS), Takeda (SS, GW), Astra Zeneca (SL, DC, SS, PB, GW, EC, BL, IVL), Daichi Sankyo (DC,SS), Roche (SL, DC, GW, EC, AA, VA, CS, TG), Merck (GW, GC,PB), Bayer (GW), Astellas (GW), PUMA biotech (JB), Gilead (SL, SS, GC, PB), Eli Lilly (SS, SL, EC, PB), Glaxo Smith Kline (GW, PB, AA, VA, TG, CS), Libos (GW), Boehringer Ingelheim (PB), Greenwich Lifesciences (EC), Nektar (PB), Exact Sciences (DC), Ely Lilly (DC), Menarini (DC), Resilience Care (IVL), Pfizer Edimark (IVL), Sandoz (IVL), Chugai (IVL), Servier Monde (IVL),Doctaform Medical Market-ing (IVL), Nektar Therapeutics (SL),No Conflicts to DeclareAU.
